— Know what they know.
Not Investment Advice
Also trades as: KHRWF (OTC) · $vol 0M · KHRN.V (TSXV) · $vol 0M

KHRNF OTC

Khiron Life Sciences Corp.
1W: +900.0% 1M: +900.0% 3M: +0.0% YTD: +0.0% 1Y: +0.0% 3Y: -100.0% 5Y: -100.0%
$0.00
+0.00 (+0.00%)
 
OTC · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Neutral · Power 61 · $2324 mcap · 205M float · 0.0069% daily turnover
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.0M
52W Range0.000001-0.0001
Volume15,039
Avg Volume14,044
Beta5.43
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOAlvaro Francisco Torres
Employees310
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2021-01-08
Websitekhiron.ca
500 Burrard Street
Vancouver, BC V6C 2B5
CA
647 556-5750
About Khiron Life Sciences Corp.

Khiron Life Sciences Corp. operates as a comprehensive medical and cannabis enterprise, extending its operations across Latin America and Europe. The company's business is structured into three primary segments: Health Services, Medical Cannabis Products, and Wellbeing Products. A core focus for Khiron involves the end-to-end process of medical cannabis, encompassing the cultivation, manufacturing, distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) varieties. Additionally, the company manages a network of health centers and satellite clinics, notably under the ILANS and Zerenia brands. It also develops CBD-based cosmeceutical items, specifically marketed under its Kuida brand. Its healthcare footprint includes running Zerenia clinics in key locations such as Medellin and Peru. Khiron Life Sciences Corp. was founded in 2012 and maintains its corporate headquarters in Vancouver, Canada.

Latest News
No recent news

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms